Patent intelligence · US
US 8652516
Doxycycline formulations, and methods of treating rosacea
Doxycycline formulations, and methods of treating rosacea
Patent details — US 8652516
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 18, 2014
- Expiration
- Feb 13, 2034
- Applicant
- Cerovene, Inc.
- Claims
- 29
- CPC classes
- A61K, A61K31/65, A61K9/0053, A61K9/4808
Quick answer
US 8652516 (Doxycycline formulations, and methods of treating rosacea) is held by Cerovene, Inc.. Status: granted. Granted Feb 18, 2014. Expires Feb 13, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cerovene, Inc.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61K, A61K31/65, A61K9/0053, A61K9/4808, A61K9/4825, A61K9/4866
More from Cerovene, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12303551
Cellular immunotherapy compositions and uses thereof
granted -
US 12291557
Chimeric TIM4 receptors and uses thereof
granted -
US 11708423
Chimeric engulfment receptor molecules and methods of use
granted -
US 11697689
Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs
granted -
US 11655282
Chimeric engulfment receptor molecules
granted -
US 10675246
Orally administrable compositions comprising calcium
granted -
US 10307410
Mcl-1 modulating compounds for cancer treatment
granted -
US 10273307
Humanized anti-CD134 (OX40) antibodies and uses thereof
granted
Frequently asked questions
What is US patent 8652516?
US 8652516 (Doxycycline formulations, and methods of treating rosacea) is held by Cerovene, Inc.. Status: granted. Granted Feb 18, 2014. Expires Feb 13, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8652516?
Cerovene, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 8652516 expire?
Our index shows an expiration date of Feb 13, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.